PHVS Stock Overview
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases.
Pharvaris N.V. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.55|
|52 Week High||US$27.50|
|52 Week Low||US$5.38|
|1 Month Change||-40.96%|
|3 Month Change||-76.67%|
|1 Year Change||-68.70%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-80.86%|
Recent News & Updates
We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Pharvaris GAAP EPS of -€0.38
Pharvaris press release (NASDAQ:PHVS): Q2 GAAP EPS of -€0.38. Cash and cash equivalents were €201 million as of June 30, 2022, compared to €209 million as of December 31, 2021.
Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate
Pharvaris N.V. (NASDAQ:PHVS) dropped ~19% in the pre-market trading Monday after the Dutch biopharma announced that the FDA verbally notified its plans to issue a clinical hold on the clinical trials of hereditary angioedema candidate PHA121. The decision is based on a review of nonclinical data, and the agency intends to offer a formal clinical hold letter within the next 30 days. A small molecule bradykinin B2-receptor antagonist, PHA121, was undergoing clinical studies in the U.S. under two Investigational New Drug (IND) applications for HAE. “We are fully committed to working closely with the FDA to address the agency’s concerns,” PHVS Chief Executive Berndt Modig remarked.
|PHVS||US Pharmaceuticals||US Market|
Return vs Industry: PHVS underperformed the US Pharmaceuticals industry which returned 4.4% over the past year.
Return vs Market: PHVS underperformed the US Market which returned -20% over the past year.
|PHVS Average Weekly Movement||14.3%|
|Pharmaceuticals Industry Average Movement||11.3%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: PHVS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: PHVS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
|2015||47||Berndt Axel Modig||https://pharvaris.com|
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial.
Pharvaris N.V. Fundamentals Summary
|PHVS fundamental statistics|
Is PHVS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PHVS income statement (TTM)|
|Cost of Revenue||€0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.48|
|Net Profit Margin||0.00%|
How did PHVS perform over the long term?See historical performance and comparison